Metaglip is a fixed-dose combination tablet containing glipizide (a sulfonylurea) and metformin (a biguanide), used twice daily with meals to treat type 2 diabetes in adults. The pairing combines two complementary mechanisms — glipizide stimulates insulin release from the pancreas, and metformin reduces hepatic glucose production and improves insulin sensitivity. A1C reductions typically run 1.0 to 2.0 percentage points; hypoglycemia and modest weight gain are the most relevant downsides.
What Metaglip Is
Metaglip combines glipizide and metformin hydrochloride in a single tablet. Originally marketed by Bristol-Myers Squibb, it is now widely available as a generic. Available strengths are:
- 2.5 mg glipizide / 250 mg metformin
- 2.5 mg glipizide / 500 mg metformin
- 5 mg glipizide / 500 mg metformin
Glipizide closes ATP-sensitive potassium channels on pancreatic beta cells, triggering insulin secretion regardless of meal timing — which is why it is taken with food to align insulin release with glucose. Metformin acts mainly in the liver, suppressing gluconeogenesis, and to a smaller degree improves peripheral insulin sensitivity and reduces intestinal glucose absorption.
Who Metaglip Is For
- Adults with type 2 diabetes whose blood sugar is inadequately controlled by diet and exercise alone (initial therapy)
- Adults inadequately controlled on glipizide monotherapy or metformin monotherapy
- Patients who prefer a single tablet over two separate pills
- Patients seeking a low-cost generic combination
It is not appropriate for type 1 diabetes, diabetic ketoacidosis, severe kidney impairment (eGFR below 30), or active liver disease. Pregnancy and lactation generally call for different therapy.
Metaglip at a Glance
| Feature | Detail |
|---|---|
| Generic ingredients | Glipizide + metformin HCl |
| Drug classes | Sulfonylurea + biguanide |
| Indication | Type 2 diabetes (adults) |
| Route | Oral tablet |
| Frequency | Twice daily with meals |
| Starting dose (initial therapy) | 2.5/250 mg once daily with breakfast |
| Starting dose (replacing monotherapy) | 2.5/500 mg or 5/500 mg twice daily |
| Maximum daily dose | 20 mg glipizide + 2000 mg metformin |
| Titration interval | Every 2 weeks based on response |
| A1C reduction | 1.0 to 2.0 percentage points |
| Weight effect | +1 to +3 kg typical (sulfonylurea-driven) |
| Hypoglycemia risk | Moderate |
| Cost (generic) | Low (often under $20/month) |
Benefits of the Combination
- Two complementary mechanisms in one tablet improve adherence
- Faster A1C reduction than either drug alone
- Lower total dose of each component than if used as monotherapy
- Generic availability keeps cost very low compared with newer agents
- Long clinical track record — both drugs have decades of use
- Useful when metformin alone is inadequate and cost is a barrier to GLP-1 or SGLT2 inhibitor add-on
How to Take Metaglip
- Take with meals — typically breakfast and dinner, 12 hours apart
- Swallow whole; do not crush, split, or chew
- Do not skip meals after a dose — this raises hypoglycemia risk
- Start at the lowest strength when adding to diet and exercise; titrate slowly every 2 weeks to avoid GI side effects
- Stop the day before iodinated contrast imaging if eGFR is between 30 and 60; resume 48 hours after if kidney function is stable
- Hold during acute illness with vomiting, dehydration, or hypoxia
- Recheck A1C every 3 months until at goal, then every 6 months
Common Side Effects
- From metformin — diarrhea, nausea, abdominal cramping, metallic taste, decreased appetite; usually improve over 2 to 4 weeks
- From glipizide — hypoglycemia (low blood sugar), weight gain of 1 to 3 kg, occasional skin rash
- Headache
- Dizziness
- Increased risk of hypoglycemia with alcohol
Serious but Rare Risks
- Lactic acidosis — boxed warning for metformin; rare but serious. Risk increases with renal impairment, dehydration, sepsis, heart failure, or alcohol misuse. Symptoms include muscle pain, difficulty breathing, severe weakness, and abdominal pain.
- Severe hypoglycemia — particularly with skipped meals, exercise, alcohol, or kidney decline; can cause loss of consciousness and seizures.
- Cardiovascular concerns — older trial data raised concerns about sulfonylureas and cardiovascular mortality; newer trials (e.g., CAROLINA) suggest cardiovascular neutrality versus DPP-4 inhibitors, but sulfonylureas lack the cardioprotection of GLP-1 RAs and SGLT2 inhibitors.
- Vitamin B12 deficiency — long-term metformin can lower B12 levels; check every 1 to 2 years.
- Hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Cholestatic jaundice (rare)
Drug Interactions
- Beta blockers — may mask hypoglycemia symptoms
- NSAIDs, ACE inhibitors — may worsen renal function, increasing metformin risk
- Iodinated contrast agents — temporarily hold
- Alcohol — increases hypoglycemia and lactic acidosis risk
- CYP2C9 inhibitors (fluconazole) — increase glipizide levels
- Corticosteroids, thiazides — antagonize glycemic effect
How Metaglip Compares to Newer Combinations
| Combination | A1C drop | Weight | CV/Kidney benefit | Cost |
|---|---|---|---|---|
| Metaglip (glipizide + metformin) | 1.0–2.0% | +1 to +3 kg | Neutral | Very low |
| Janumet (sitagliptin + metformin) | 0.8–1.5% | Neutral | Neutral | Moderate–high |
| Synjardy (empagliflozin + metformin) | 0.8–1.5% | −2 to −3 kg | CV and renal benefit | High |
| Segluromet (ertugliflozin + metformin) | 0.8–1.3% | −2 to −3 kg | Modest CV benefit | High |
| Xigduo XR (dapagliflozin + metformin) | 0.8–1.5% | −2 to −3 kg | HF and renal benefit | High |
For people without significant cardiovascular disease, heart failure, or chronic kidney disease, Metaglip remains a reasonable, low-cost option. For those with CV disease, heart failure, or CKD, the 2024 ADA Standards of Care prioritize SGLT2 inhibitor- or GLP-1-based combinations because of organ-protective benefits beyond A1C.
Cost and Access
Generic glipizide-metformin is widely available at $5 to $20 for a 30-day supply at most pharmacies, with discount cards lowering costs further. This makes Metaglip one of the most affordable diabetes combinations on the market — relevant when out-of-pocket cost is the main barrier to adherence.
Lifestyle Considerations
Medication works best alongside diet, weight management, and physical activity. Read more about diet for blood sugar control and reversing prediabetes.
The Bottom Line
Metaglip combines glipizide and metformin into one tablet for adults with type 2 diabetes, taken twice daily with meals. It lowers A1C by 1.0 to 2.0 percentage points and is widely available as a low-cost generic. The trade-offs are hypoglycemia risk and modest weight gain from the sulfonylurea component, plus the usual metformin GI side effects. For patients with cardiovascular disease, heart failure, or chronic kidney disease, modern combinations using SGLT2 inhibitors or GLP-1 receptor agonists offer additional organ protection that sulfonylurea-based pairings do not. Talk to your doctor about which combination best matches your A1C target, weight goals, and cardiovascular profile.
